XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Principal repayments         $ 8,787 $ 35,596    
Interest income         105,765 183,416    
Outstanding principal balance         1,445,303   $ 1,569,675  
General and administrative expenses         $ 231,750 0    
Common stock share issued         17,834,023   15,982,472  
Accounts receivable balance         $ 19,070,104   $ 19,759,254  
Prepaid expenses and other current assets - related party         1,895,857   1,811,911  
Revenue         14,584,473 12,349,777    
George Terzis [Member]                
Unpaid salaries and bonuses         398,000   98,000  
Grigorios Siokas [Member]                
Outstanding principal balance         5,379   13,257  
Foreign curreny translation         (325) (208)    
Cana Holdings Laboratories Holding Limited [Member]                
Secured promissory note     $ 4,457,520          
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023)          
DOC Pharma S.A. [Member]                
Principal repayments         107,910      
Interest repayments         44,324      
Interest income         $ 53,235      
Prepaid expenses               $ 7,599,545
Interest rate         5.50%      
Loan term         10 years      
Maturity date         Dec. 01, 2032      
Accounts payable and accrued expenses - related party         $ 92,287   34,217  
Prepaid balance             4,279,200  
Accounts receivable - related party         2,539,336   2,386,721  
Prepaid expenses and other current assets - related party         5,130,847   4,347,184  
Revenue         $ 84,321 627    
Agreement terminate         Dec. 31, 2025      
Pieces per product         1,000 pieces      
Purchased of additional licenses         $ 0   525,461  
Loan current portion         431,640   442,480  
Loan non-current portion         3,345,210   3,539,840  
Inventroy purchase         189,048 450,911    
Monthly basis instalments         35,660      
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022        
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600            
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                
Inventroy purchase         70,732 401,786    
Dimitrios Goulielmos [Member]                
Outstanding principal balance         11,007   11,283  
Foreign curreny translation         (276) (177)    
Panagiotis Kozaris [Member]                
Shares owned         0   51,159  
Prepaid expenses         194,215   194,215  
Maria Kozari [Member]                
Accounts receivable balance         1,148,687   1,142,402  
Net sales         86,678 $ 118,987    
Kanarogloy & Sia Epe [Member]                
Accounts payable and accrued expenses - related party         48,495   85,332  
Basotho Investment Limited [Member]                
General and administrative expenses         $ 30,900   $ 10,300  
Common stock share issued             120,000